Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases ...
SONFH is one of the leading causes of non-traumatic osteonecrosis. Reported in up to 9%–40% of patients receiving prolonged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results